These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22318866)

  • 1. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy.
    Noguchi T; Kato T; Wang L; Maeda Y; Ikeda H; Sato E; Knuth A; Gnjatic S; Ritter G; Sakaguchi S; Old LJ; Shiku H; Nishikawa H
    Cancer Res; 2012 Apr; 72(7):1672-82. PubMed ID: 22318866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
    Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
    Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
    Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
    J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber.
    Slager EH; van der Minne CE; Goudsmit J; van Oers JM; Kostense S; Havenga MJ; Osanto S; Griffioen M
    Cancer Gene Ther; 2004 Mar; 11(3):227-36. PubMed ID: 14726960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
    Nishikawa H; Sato E; Briones G; Chen LM; Matsuo M; Nagata Y; Ritter G; Jäger E; Nomura H; Kondo S; Tawara I; Kato T; Shiku H; Old LJ; Galán JE; Gnjatic S
    J Clin Invest; 2006 Jul; 116(7):1946-54. PubMed ID: 16794737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
    Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
    Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fucoidin enhances dendritic cell-mediated T-cell cytotoxicity against NY-ESO-1 expressing human cancer cells.
    Hu Y; Cheng SC; Chan KT; Ke Y; Xue B; Sin FW; Zeng C; Xie Y
    Biochem Biophys Res Commun; 2010 Feb; 392(3):329-34. PubMed ID: 20067767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.
    Gupta A; Nuber N; Esslinger C; Wittenbrink M; Treder M; Landshammer A; Noguchi T; Kelly M; Gnjatic S; Ritter E; von Boehmer L; Nishikawa H; Shiku H; Old L; Ritter G; Knuth A; van den Broek M
    Cancer Immun; 2013; 13():3. PubMed ID: 23390374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
    Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
    Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
    Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
    Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
    Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
    Ellenhorn JD; Schreiber H; Bluestone JA
    J Immunol; 1990 Apr; 144(7):2840-6. PubMed ID: 1969454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.